GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
Through the specific and tight interaction between streptavidin and biotin, a novel platform was developed to allow for rapid (less than 2h), efficient and durable display of streptavidin-tagged bioactive GM-CSF on the surface of biotinylated B16.F10 tumor cells. This technology involved biotinylation of the cell membrane with a biotin derivative and surface modification of the biotinylated cells with the bi-functional fusion protein, streptavidin-tagged GM-CSF. Furthermore, the resultant GM-CSF-modified B16.F10 whole tumor cell vaccine could induce strong and long-lasting systemic protection against the wild-type tumor challenge. Therefore, the platform may represent a fast, efficient and safe approach for the whole tumor cell vaccination.
Gao
Jimin
J
Institute of Molecular Immunology, College of Biotechnology, Southern Medical University, 1838 Guangzhou Dadao Bei, Guangzhou, Guangdong 510515, China. jimingao@yahoo.com
Huang
Shuqi
S
Li
Ming
M
Luo
Rongcheng
R
Wang
Xiaoning
X
Takashima
Akira
A
D000818:Animals; D019921:Biotinylation; D019496:Cancer Vaccines / Q000008:administration & dosage*; D045744:Cell Line, Tumor / Q000528:radiation effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D011993:Recombinant Fusion Proteins; D019809:Streptavidin; D014611:Vaccination
D019496:Cancer Vaccines; D011993:Recombinant Fusion Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D019809:Streptavidin